Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Buguzhi total glycosides is a standardized botanical extract derived from the seeds of *Psoralea corylifolia* L. (Buguzhi), a traditional Chinese medicinal herb. Developed by the Jiangsu Provincial Academy of Traditional Chinese Medicine, this pharmaceutical candidate is specifically formulated for the treatment of primary osteoporosis. The extract is enriched with bioactive glycosides and flavonoids that function as phytoestrogens. Its mechanism of action involves the modulation of bone metabolism by promoting osteoblast differentiation and bone formation while simultaneously inhibiting osteoclast-mediated bone resorption. These effects are primarily mediated through the activation of estrogen receptors (ERα and ERβ) and the stimulation of the Wnt/β-catenin signaling pathway, leading to improved bone mineral density and strengthened bone microarchitecture.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on buguzhi total glycosides.